AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19587362 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of aliskiren and irbesartan
Number of subjects: 26
Study 19587362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 16999946 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg of simvastatin
Number of subjects: 42
Study 16999946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 15083439 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional task practice (FT)
Number of subjects: 64
Study 15083439 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (ST)
Number of subjects: 64
Study 15083439 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 64
Study 11398568 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategies to overcome barriers to participation in research
Number of subjects: 0
Study 9796243 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-regulated Volume Control (PRVC)
Number of subjects: 9
Study 9796243 — intervention group
Group type: COMPARATOR
Intervention: Volume Controlled ventilation (VC)
Number of subjects: 9
Study 7816516 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral feeding
Number of subjects: 8
Study 7816516 — intervention group
Group type: COMPARATOR
Intervention: Parenteral nutrition
Number of subjects: 8
Study 7816516 — intervention group
Group type: EXPERIMENTAL
Intervention: Both enteral and parenteral feeding
Number of subjects: 8
Study 29196578 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine (300 mg/d)
Number of subjects: 6
Study 29196578 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine (900 mg/d and 600 mg/d)
Number of subjects: 6
Study 29196578 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine
Number of subjects: 6
Study 26603881 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic (50% inulin and 50% fructo-oligosaccharide), 6 g twice daily from 1 week before to 3 weeks after RT
Number of subjects: 38
Study 26603881 — intervention group
Group type: COMPARATOR
Intervention: Placebo (6 g maltodextrin twice daily from 1 week before to 3 weeks after RT)
Number of subjects: 38
Study 25464565 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐methionine tablets
Number of subjects: 203
Study 25464565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study 22540883 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide + metformin
Number of subjects: 174
Study 22540883 — intervention group
Group type: COMPARATOR
Intervention: Placebo + metformin
Number of subjects: 174
Study 20822421 — intervention group
Group type: EXPERIMENTAL
Intervention: Nissen fundoplication
Number of subjects: 175
Study 20822421 — intervention group
Group type: COMPARATOR
Intervention: Thal fundoplication
Number of subjects: 175
Study 18990592 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote endarterectomy (RSFAE)
Number of subjects: 116
Study 18990592 — intervention group
Group type: COMPARATOR
Intervention: Supragenicular bypass surgery
Number of subjects: 116
Study 18990592 — intervention group
Group type: EXPERIMENTAL
Intervention: Venous grafts
Number of subjects: 116
Study 18990592 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosthetic grafts
Number of subjects: 116
Study 16960175 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 IU vitamin D3/d for 2 years, then increased to 2000 IU/d
Number of subjects: 208
Study 16960175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study 14738835 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydrogen peroxide (Xtra White)
Number of subjects: 20
Study 14738835 — intervention group
Group type: COMPARATOR
Intervention: 18% carbamide peroxide (Colgate Simply White)
Number of subjects: 20
Study 11408327 — intervention group
Group type: EXPERIMENTAL
Intervention: Area Dentata (AD) in autistic patients
Number of subjects: 59
Study 11408327 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined area of the subiculum and CA1-CA3 (CAS) in autistic patients
Number of subjects: 59
Study 11408327 — intervention group
Group type: COMPARATOR
Intervention: Healthy normal controls
Number of subjects: 59
Study 9416862 — intervention group
Group type: EXPERIMENTAL
Intervention: Juvenile rheumatoid arthritis (JRA) cases
Number of subjects: 50
Study 8120156 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 75
Study 8120156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 3616532 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular home visits over a period of three years
Number of subjects: 25
Study 3616532 — intervention group
Group type: COMPARATOR
Intervention: Control group (not contacted until the conclusion of the study period)
Number of subjects: 25
Study 3616532 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular home visits
Number of subjects: 25
Study 31667992 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive protocol
Number of subjects: 57
Study 31667992 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboelastometry-guided protocol
Number of subjects: 57
Study 31667992 — intervention group
Group type: COMPARATOR
Intervention: Coagulogram-guided protocol
Number of subjects: 57
Study 31667992 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive protocol vs Coagulogram-guided arm
Number of subjects: 57
Study 31667992 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive protocol vs Thromboelastometry-guided arm
Number of subjects: 57
Study 31667992 — intervention group
Group type: COMPARATOR
Intervention: Thromboelastometry-guided vs Coagulogram-guided arm
Number of subjects: 57
Study 31667992 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall comparison
Number of subjects: 57
Study 29845932 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised supported self-management (SSM)
Number of subjects: 82
Study 29845932 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 82
Study 29845932 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational study measures
Number of subjects: 82
Study 27918443 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive Leaf Extract (OLE) 20 mL daily for 8 weeks
Number of subjects: 29
Study 27918443 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 29
Study 23962455 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept (125 mg weekly)
Number of subjects: 646
Study 23962455 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab (40 mg bi-weekly)
Number of subjects: 646
Study 22648709 — intervention group
Group type: EXPERIMENTAL
Intervention: Alginate-based preload supplement (15 g fiber)
Number of subjects: 96
Study 22648709 — intervention group
Group type: COMPARATOR
Intervention: Placebo preload supplement
Number of subjects: 96
Study 22648709 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (ITT analysis)
Number of subjects: 96
Study 20697939 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at acupoints Zhongwan (CV 12), bilateral Zusanli (ST36), Sanyinjiao (SP6), and Neiguan (PC6), once a day for 1 week, with intervals of 2-3 days between courses, for a total duration of 6 weeks.
Number of subjects: 60
Study 20697939 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg twice a day and 20 mg mosapride thrice a day for a total duration of 6 weeks.
Number of subjects: 60
Study 17996436 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 5 microg via Respimat SMI
Number of subjects: 719
Study 17996436 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 10 microg via Respimat SMI
Number of subjects: 719
Study 17996436 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium 36 microg pMDI QID
Number of subjects: 719
Study 17996436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 719
Study 15941145 — intervention group
Group type: COMPARATOR
Intervention: Allicor (Allium sativum preparation) for 12 months
Number of subjects: 79
Study 12874191 — intervention group
Group type: EXPERIMENTAL
Intervention: FilterWire EX
Number of subjects: 651
Study 12874191 — intervention group
Group type: COMPARATOR
Intervention: GuardWire
Number of subjects: 651
Study 10577446 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecadotril 50 to 400 mg twice daily
Number of subjects: 50
Study 10577446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 8762732 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexarelin (1 microgram/kg)
Number of subjects: 6
Study 8762732 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH-(1-29)-NH2 (1 microgram/kg)
Number of subjects: 6
Study 8762732 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexarelin with GHRH-(1-29)-NH2
Number of subjects: 6
Study 8762732 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 6
Study 8762732 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexarelin (second bolus)
Number of subjects: 6
Study 8762732 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexarelin with GHRH-(1-29)-NH2 (second bolus)
Number of subjects: 6
Study 1678221 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine (1, 3.3, 10, 33, and 100 micrograms/ml) injected intradermally
Number of subjects: 15
Study 7055526 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia with thiopentone, fentanyl and nitrous oxide, infusion of isotonic saline solution 5ml min‐1 (Group I)
Number of subjects: 19
Study 7055526 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia with thiopentone, fentanyl and nitrous oxide, infusion of isotonic saline solution 15 ml min‐1 (Group II)
Number of subjects: 19
Study 7055526 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural anaesthesia (Group III)
Number of subjects: 19
Study 31285367 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving and returning surveys in the clinic
Number of subjects: 0
Study 31285367 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving and returning surveys by email
Number of subjects: 0
Study 31285367 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving and returning surveys in the clinic (Study 2)
Number of subjects: 0
Study 31285367 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving surveys in preferred mode (Study 2)
Number of subjects: 0
Study 29241582 — intervention group
Group type: EXPERIMENTAL
Intervention: 10/20‐PRO (10 g protein followed by 20 g whey protein isolate 120 minutes later)
Number of subjects: 12
Study 29241582 — intervention group
Group type: EXPERIMENTAL
Intervention: 30‐PRO (30 g protein breakfast)
Number of subjects: 12
Study 29241582 — intervention group
Group type: COMPARATOR
Intervention: 10‐PRO (10 g protein breakfast, control)
Number of subjects: 12
Study 25644442 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NACT)
Number of subjects: 0
Study 25644442 — intervention group
Group type: COMPARATOR
Intervention: Primary debulking surgery (PDS)
Number of subjects: 0
Study 24307240 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP5 (five-component acellular pertussis vaccine)
Number of subjects: 0
Study 24307240 — intervention group
Group type: EXPERIMENTAL
Intervention: DTwP (whole-cell pertussis vaccine)
Number of subjects: 0
Study 24307240 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP2 (two-component acellular pertussis vaccine)
Number of subjects: 0
Study 24307240 — intervention group
Group type: COMPARATOR
Intervention: No vaccine (1997 seroprevalence study)
Number of subjects: 0
Study 24307240 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP2 or DTaP3 (2007 seroprevalence study)
Number of subjects: 0
Study 23013200 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced meter features (AMF group)
Number of subjects: 211
Study 23013200 — intervention group
Group type: COMPARATOR
Intervention: Basic meter features (BMF group)
Number of subjects: 211
Study 20214328 — intervention group
Group type: EXPERIMENTAL
Intervention: Western medical routine therapy combined with QQG
Number of subjects: 82
Study 20214328 — intervention group
Group type: COMPARATOR
Intervention: Western medical routine therapy with placebo
Number of subjects: 82
Study 17576355 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementarity conditions (women high in IO working with a friendly confederate)
Number of subjects: 0
Study 17576355 — intervention group
Group type: COMPARATOR
Intervention: Noncomplementarity conditions (women low in IO working with a friendly confederate, women high in IO working with an unfriendly confederate)
Number of subjects: 0
Study 15590360 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/day
Number of subjects: 108
Study 15590360 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/day + vitamin C 500 mg/day
Number of subjects: 108
Study 15590360 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/day + vitamin E 400 IU/day
Number of subjects: 108
Study 15590360 — intervention group
Group type: COMPARATOR
Intervention: Control group (simvastatin alone)
Number of subjects: 108
Study 11328193 — intervention group
Group type: EXPERIMENTAL
Intervention: Losigamone (3x500 mg/die)
Number of subjects: 203
Study 11328193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study 9208340 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurythromycin ethylsuccinate
Number of subjects: 152
Study 9208340 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin
Number of subjects: 152
Study 7960298 — intervention group
Group type: EXPERIMENTAL
Intervention: Urban youth
Number of subjects: 0
Study 7960298 — intervention group
Group type: EXPERIMENTAL
Intervention: Rural youth
Number of subjects: 0
Study 7960298 — intervention group
Group type: EXPERIMENTAL
Intervention: Semiurban youth
Number of subjects: 0
Study 7960298 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana initiation
Number of subjects: 0
Study 7960298 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol initiation
Number of subjects: 0
Study 3110200 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DXM) 2.25 mg/day
Number of subjects: 22
Study 3110200 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DXM)
Number of subjects: 22
Study 3110200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 31898776 — intervention group
Group type: EXPERIMENTAL
Intervention: PSVPro
Number of subjects: 70
Study 31898776 — intervention group
Group type: COMPARATOR
Intervention: PCV
Number of subjects: 70
Study 31833464 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care-based group educational intervention about pain neuroscience
Number of subjects: 54
Study 31833464 — intervention group
Group type: COMPARATOR
Intervention: Routine medical care (Control)
Number of subjects: 54
Study 28825650 — intervention group
Group type: EXPERIMENTAL
Intervention: Wellness framing (emphasizing promoting health and quitting support)
Number of subjects: 1885
Study 28825650 — intervention group
Group type: EXPERIMENTAL
Intervention: Punitive framing (emphasizing consequences for violating the policy)
Number of subjects: 1885
Study 28825650 — intervention group
Group type: COMPARATOR
Intervention: Control (no message)
Number of subjects: 1885
Study 28825650 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers who correctly reported the message they received
Number of subjects: 1885
Study 25331194 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulations containing HPC with intrinsic viscosities above 9 dL/g and in quantities above 30%
Number of subjects: 0
Study 25331194 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulations containing HPMC with intrinsic viscosities above 9 dL/g and in quantities above 30%
Number of subjects: 0
Study 25331194 — intervention group
Group type: COMPARATOR
Intervention: Fasted and fed conditions
Number of subjects: 0
Study 25331194 — intervention group
Group type: EXPERIMENTAL
Intervention: HPC matrices
Number of subjects: 0
Study 24780407 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose subconjunctival cyclosporine A (CsA) implants
Number of subjects: 97
Study 24780407 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose subconjunctival cyclosporine A (CsA) implants
Number of subjects: 97
Study 24780407 — intervention group
Group type: COMPARATOR
Intervention: Placebo (carrier only) implants
Number of subjects: 97
Study 22782607 — intervention group
Group type: EXPERIMENTAL
Intervention: Weaning protocol group (PG)
Number of subjects: 731
Study 22782607 — intervention group
Group type: COMPARATOR
Intervention: Non-protocol group (NPG)
Number of subjects: 731
Study 22782607 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 731
Study 19848312 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 696
Study 19848312 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 696
Study 17695389 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite cement (HAC) reconstruction
Number of subjects: 130
Study 17695389 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HAC reconstruction)
Number of subjects: 130
Study 15450783 — intervention group
Group type: COMPARATOR
Intervention: Polymorphism ‐602G> A
Number of subjects: 104
Study 15450783 — intervention group
Group type: COMPARATOR
Intervention: Haplotypes consisting of ‐602G> A and ‐3542G> A
Number of subjects: 104
Study 11725616 — intervention group
Group type: EXPERIMENTAL
Intervention: Early removal of nasogastric tube (NGT)
Number of subjects: 100
Study 11725616 — intervention group
Group type: COMPARATOR
Intervention: Maintenance of nasogastric tube (NGT) until passage of flatus/feces
Number of subjects: 100
Study 9578342 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant fortified margarine (15 g/d providing 121 mg vitamin C, 31 mg vitamin E, 2.7 mg alpha‐carotene, and 5.3 mg beta‐carotene)
Number of subjects: 31
Study 9578342 — intervention group
Group type: COMPARATOR
Intervention: Ordinary margarine
Number of subjects: 31
Study 18800453 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan potassium 50 mg once or twice daily, or 100 mg once daily
Number of subjects: 122
Study 18800453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 2804253 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of test or reference drug
Number of subjects: 0
Study 2804253 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple dose of test or reference drug
Number of subjects: 0
Study 2804253 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of phenytoin
Number of subjects: 0
Study 2804253 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple dose of phenytoin
Number of subjects: 0
Study 985661 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin 1.5 mg/kg or 80 mg administered via rapid intravenous injection
Number of subjects: 0
Study 985661 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin dosage interval of 6 hr with a total dosage of 6 mg/kg per day
Number of subjects: 0
Study 30444982 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine gel (20 mL of 2% lidocaine gel)
Number of subjects: 215
Study 30444982 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 215
Study 30444982 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine gel
Number of subjects: 215
Study 28692301 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D3 (3.5 mg or 140,000 IU biweekly for 8 weeks)
Number of subjects: 390
Study 28692301 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D3
Number of subjects: 390
Study 25687878 — intervention group
Group type: EXPERIMENTAL
Intervention: Active GVS during training
Number of subjects: 30
Study 25687878 — intervention group
Group type: COMPARATOR
Intervention: Placebo GVS (controls)
Number of subjects: 30
Study 25687878 — intervention group
Group type: EXPERIMENTAL
Intervention: Context-Consistent group
Number of subjects: 30
Study 25687878 — intervention group
Group type: EXPERIMENTAL
Intervention: Context-Change group
Number of subjects: 30
Study 24147466 — intervention group
Group type: EXPERIMENTAL
Intervention: High-pitch ECG-synchronized pulmonary CTA
Number of subjects: 47
Study 24147466 — intervention group
Group type: COMPARATOR
Intervention: Standard pulmonary CTA
Number of subjects: 47
Study 21135313 — intervention group
Group type: EXPERIMENTAL
Intervention: Open treatment with citalopram followed by up to 3 sequential next‐step treatments.
Number of subjects: 4041
Study 19467441 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodogram spectral analysis
Number of subjects: 201
Study 19467441 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoregressive (AR) modelling
Number of subjects: 201
Study 17372316 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat load (liquid test meal challenge containing 95% fat)
Number of subjects: 701
Study 15488139 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting of renal artery
Number of subjects: 27
Study 15488139 — intervention group
Group type: COMPARATOR
Intervention: Control group (medical treatment only)
Number of subjects: 27
Study 11240973 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (50 mg twice a day for 7 days) + Mexiletine (200 mg on the eighth day)
Number of subjects: 6
Study 11240973 — intervention group
Group type: COMPARATOR
Intervention: Mexiletine (200 mg alone)
Number of subjects: 6
Study 9448754 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D fat-suppressed echo planar imaging (EPI) sequence
Number of subjects: 20
Study 9448754 — intervention group
Group type: COMPARATOR
Intervention: 3D fat-suppressed gradient echo (GE) sequence
Number of subjects: 20
Study 7755478 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril (CIL) 10 mg per day (n=6)
Number of subjects: 13
Study 7755478 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) (n=7)
Number of subjects: 13
Study 2790919 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine sulphate, 20 mg/day for one year
Number of subjects: 0
Study 2790919 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 1255309 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloramphenicol treatment
Number of subjects: 50
Study 1255309 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin treatment
Number of subjects: 50
Study 30678744 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual psychological treatments (Healthy Activity Program for depression)
Number of subjects: 222
Study 30678744 — intervention group
Group type: COMPARATOR
Intervention: mhGAP-based services by primary health workers
Number of subjects: 222